Join Dr. Tania Small, head of Medical Affairs at Bristol Myers Squibb, for a forward-looking episode of DoctoRx Unscripted, featuring leading thoracic oncologists Dr. Christine Lovly and Dr. Nate Pennell. Together, they examine innovations redefining what’s possible for patients with lung cancer:

• Biomarker-driven therapy and molecular profiling;
• Liquid biopsy and ctDNA testing;
• AI-assisted detection and radiomics; and
• Next-generation immunotherapies, including bispecifics, T-cell engagers, and personalized vaccines.

They also share their perspectives on a critical challenge: translating scientific progress into real-world impact by expanding access and closing gaps in care. If you're working to advance oncology care—or interested in deepening your understanding of what’s shaping its future—this is a conversation you don’t want to miss.

Part 3 - The Movement

Join Dr. Tania Small, head of Medical Affairs at Bristol Myers Squibb, for a special edition of DoctoRx Unscripted, focused on hypertrophic cardiomyopathy (HCM)—one of the most common inherited cardiac diseases and one of the most frequently missed. In Part 3, Dr. Small sits down with patient advocate Lisa Salberg, founder of the Hypertrophic Cardiomyopathy Association (HCMA), to explore how a personal diagnosis evolved into a global movement—helping to establish more than 60 Centers of Excellence around the world.

The conversation reinforces why embedding the patient voice early is essential to advancing cardiovascular medicine.

Part 2 - The Shift

Join Dr. Tania Small, head of Medical Affairs at Bristol Myers Squibb, for a special edition of DoctoRx Unscripted, focused on hypertrophic cardiomyopathy (HCM)—one of the most common inherited cardiac diseases and one of the most frequently missed. In Part 2, Dr. Small welcomes HCM expert Dr. Matthew Martinez and leading cardiologist Dr. Nani Bhalla. Together, they examine why HCM has historically been so difficult to detect—and what has changed in recent years to begin altering that trajectory.

The discussion explores how earlier recognition, paired with more precise and individualized treatment decisions, can change outcomes in meaningful and lasting ways.